195 related articles for article (PubMed ID: 17229870)
1. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
Wiltshire T; Senft J; Wang Y; Konat GW; Wenger SL; Reed E; Wang W
Mol Pharmacol; 2007 Apr; 71(4):1051-60. PubMed ID: 17229870
[TBL] [Abstract][Full Text] [Related]
2. Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven.
Wang Y; Wiltshire T; Senft J; Wenger SL; Reed E; Wang W
Mol Cancer Ther; 2006 Dec; 5(12):3153-61. PubMed ID: 17172419
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis.
Cousineau I; Abaji C; Belmaaza A
Cancer Res; 2005 Dec; 65(24):11384-91. PubMed ID: 16357146
[TBL] [Abstract][Full Text] [Related]
4. ATM-dependent CHK2 activation induced by anticancer agent, irofulven.
Wang J; Wiltshire T; Wang Y; Mikell C; Burks J; Cunningham C; Van Laar ES; Waters SJ; Reed E; Wang W
J Biol Chem; 2004 Sep; 279(38):39584-92. PubMed ID: 15269203
[TBL] [Abstract][Full Text] [Related]
5. The role of the BRCA1 tumor suppressor in DNA double-strand break repair.
Zhang J; Powell SN
Mol Cancer Res; 2005 Oct; 3(10):531-9. PubMed ID: 16254187
[TBL] [Abstract][Full Text] [Related]
6. Irofulven induces replication-dependent CHK2 activation related to p53 status.
Wang Y; Wiltshire T; Senft J; Reed E; Wang W
Biochem Pharmacol; 2007 Feb; 73(4):469-80. PubMed ID: 17118344
[TBL] [Abstract][Full Text] [Related]
7. The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells.
Zhou C; Huang P; Liu J
Biochem Biophys Res Commun; 2005 Oct; 336(3):952-60. PubMed ID: 16165098
[TBL] [Abstract][Full Text] [Related]
8. Identification of sequences that target BRCA1 to nuclear foci following alkylative DNA damage.
Au WW; Henderson BR
Cell Signal; 2007 Sep; 19(9):1879-92. PubMed ID: 17531442
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine-induced DNA mismatch damage.
Yamane K; Schupp JE; Kinsella TJ
Cancer Res; 2007 Jul; 67(13):6286-92. PubMed ID: 17616687
[TBL] [Abstract][Full Text] [Related]
10. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.
Xu ZY; Loignon M; Han FY; Panasci L; Aloyz R
J Pharmacol Exp Ther; 2005 Aug; 314(2):495-505. PubMed ID: 15843498
[TBL] [Abstract][Full Text] [Related]
11. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation.
Moynahan ME; Cui TY; Jasin M
Cancer Res; 2001 Jun; 61(12):4842-50. PubMed ID: 11406561
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair.
Bolderson E; Richard DJ; Zhou BB; Khanna KK
Clin Cancer Res; 2009 Oct; 15(20):6314-20. PubMed ID: 19808869
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin.
Koehn H; Magan N; Isaacs RJ; Stowell KM
Anticancer Drugs; 2007 Apr; 18(4):419-25. PubMed ID: 17351394
[TBL] [Abstract][Full Text] [Related]
14. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the Nijmegen breakage syndrome gene leads to excess centrosome duplication via the ATR/BRCA1 pathway.
Shimada M; Sagae R; Kobayashi J; Habu T; Komatsu K
Cancer Res; 2009 Mar; 69(5):1768-75. PubMed ID: 19244116
[TBL] [Abstract][Full Text] [Related]
16. Pir51, a Rad51-interacting protein with high expression in aggressive lymphoma, controls mitomycin C sensitivity and prevents chromosomal breaks.
Henson SE; Tsai SC; Malone CS; Soghomonian SV; Ouyang Y; Wall R; Marahrens Y; Teitell MA
Mutat Res; 2006 Oct; 601(1-2):113-24. PubMed ID: 16920159
[TBL] [Abstract][Full Text] [Related]
17. Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest.
Yun J; Zhong Q; Kwak JY; Lee WH
Oncogene; 2005 Jun; 24(25):4009-16. PubMed ID: 15782115
[TBL] [Abstract][Full Text] [Related]
18. RAD51 foci formation in response to DNA damage is modulated by TIP49.
Gospodinov A; Tsaneva I; Anachkova B
Int J Biochem Cell Biol; 2009 Apr; 41(4):925-33. PubMed ID: 18834951
[TBL] [Abstract][Full Text] [Related]
19. DNA damage tumor suppressor genes and genomic instability.
Motoyama N; Naka K
Curr Opin Genet Dev; 2004 Feb; 14(1):11-6. PubMed ID: 15108799
[TBL] [Abstract][Full Text] [Related]
20. Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage.
Schonn I; Hennesen J; Dartsch DC
Apoptosis; 2010 Feb; 15(2):162-72. PubMed ID: 20041303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
